Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
The Safety of Deep Brain Stimulation in Patient's with Parkinson's Disease, E...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - DIA Presentation 2008
1. New Strategies for Successful Licensing Acquisitions Peter McFarland, PharmD Postdoctoral Fellow, Clinical Development Forest Labs, Inc. / St. John’s University
19. Strategies for Conducting New Product Scientific Assessment (Due Diligence) Yavuz S. Silay, MD,CCRP Associate Director of Clinical Science, Clinical and Medical Affairs KV Pharmaceutical, Ther-Rx and Ethex Corporations
20.
21. Overview of the Licensing Process Out-licensing In-licensing Source: MedTRACK, Sept ’07. Datamonitor Identification of the company’s limitations, and what is required to overcome these Identification of what products can be licensed and to who Performing evaluations Identification of gaps in the portfolio; Assessment of what it can offer as a partner? Evaluation of needs and identification of potential candidates Signing confidentiality agreements, drawing-up term sheets, due diligence Licensing Strategy Identifying Opportunity Licensing Evaluations Finalizing the Deal and Alliance Management
22. What therapeutic areas are more popular? Recent trends? CNS 15% Other 12% Infections 15% Cardiovascular 12% AIID 10% Cancer 7% Women’s Health 7% Digestive System 5% Multiple 4% Respiratory 5% Blood 4% Metabolic/Endocrinology 4% Marketing and Promotion Deals by therapy area, 2005-06 Source: MedTRACK, Sept ’07, Datamonitor
I’d like to welcome everyone the session. This session is entitled “New Strategies for Successful Licensing Acquisitions.” Please take a moment to silence an electronic devices you may be carrying and to get yourselves situated. Also, if you’ve just realized that you’ve ventured into the wrong room, please use this time to exit the room if need be….(2mintues). Excellent! Well it looks like most everyone who is attending the session has had a chance to settle in, so I’d like to get started. Again, I would like to welcome everyone and thank you for attending the session today. . . I’m glade you all could make it. My name is Peter McFarland. I am a PharmD Fellow at Forest Labs, Inc. and St. John’s University. I’ve been with a fellow in Clinical Development with Forest for about one year now, and one of the most intriguing aspects that I’ve noticed about the company is that they license all of their products from other companies. Now being able to see and experience this type of R&D first hand has been a great introduction into the aspects of product in-licensing, but what it has really done is sparked my interest into finding out more about the strategies that go into product licensing…. and how do we get the right products at the right time, that fit our corporate strategy? (NEXT SLIDE)